Electronic Supplementary Material (ESI) for Organic Chemistry Frontiers. This journal is © the Partner Organisations 2020

Supporting Information

For

Copper-Catalyzed 1,1-Alkynylalkylation of Alkynes: Access toward

Conjugated Enynes

Yunhe Lv,* Yanqin Wang, Weiya Pu, Xueli Zhu, Ning Wu and Yali Zhao

College of Chemistry and Chemical Engineering, Anyang Normal University, Anyang, 455000 China

luyh086@nenu.edu.cn; lvyunhe0217@163.com

Table of Contents

I . General Considerations	S2
II. General Procedure for the Preparation of 2, 3 and 4	S2
III. Analytical Data of Compounds 3 and 4	S 3
IV. Structure Analysis X-Ray Crystallography of 3b	S25
V. Mechanistic Study	S26
VI. References	S29
VII. ¹ H and ¹³ C NMR Spectra of Compounds 3 and 4	S30

I. General Considerations

All reagents were purchased from commercial sources and used without further treatment, unless otherwise indicated. The following starting materials were prepared according to the procedures described previously in the literature: **5**,^[1] **6**,^[2] **7**,^[3] **8**.^[3] All reactions were run under air with no precautions taken to exclude moisture. ¹H NMR and ¹³C NMR spectra were recorded at 25 °C on a Varian (400 MHz and 100 MHz). Melting points were obtained with a micro melting point XT4A Beijing Keyi electrooptic apparatus and are uncorrected. High-resolution mass data were recorded on a Waters LCT PremierxeTM (USA). Single-crystal X-ray crystallography was carried out on a Bruker Smart Apex II diffractometer system. All reactions were monitored by TLC with Taizhou GF254 silica gel coated plates. Flash column chromatography was carried out using 200-300 mesh silica gel at increased pressure.

II. General Procedure for the Preparation of 2, 3 and 4

1. General Procedure for the Preparation of 2

Substrates 2 were prepared by the reaction of corresponding anilines (1 equiv) and acyl chlorides (1.2 equiv) in CH_2Cl_2 at room temperature according to procedures described in the literature reported before.^[4]

2. General Procedure for the Preparation of 3 and 4

3a as an example



To a solution of the 2-chloro-*N*-(*p*-tolyl)acetamide **2a** (73.2 mg, 0.4 mmol) in 1,4-dioxane (0.8 ml) was added the ethynylbenzene **1a** (110 μ L, 0.96 mmol), Phen (7.9 mg, 0.04 mmol), CuI (7.6 mg, 0.04 mmol), and K₂CO₃ (110.6 mg, 0.8 mmol) under air in a Schlenck tube. The reaction mixture was stirred at 120 °C for 1.0 h. After the reaction finished, the reaction mixture was

cooled to room temperature and quenched by water. The mixture was extracted with EtOAc (3.0 mL×3), the combined organic phases were dried over anhydrous Na_2SO_4 and the solvent was evaporated under vacuum. The residue was purified by column chromatography to give the corresponding products **3a** (112.0 mg, 80%).

III. Analytical Data of Compounds 3 and 4



(E)-3-benzylidene-5-phenyl-N-(p-tolyl)pent-4-ynamide 3a

White solid. mp: 140 °C. ¹H NMR (400 MHz, CDCl₃): δ = 2.30 (s, 3H), 3.55 (s, 2H), 7.10 (d, *J* = 8.0 Hz, 2H), 7.23 (s, 1H), 7.29-7.34 (m, 4H), 7.37-7.40 (m, 6H), 7.47 (t, *J* = 3.6 Hz, 2H), 7.79 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 20.8, 41.3, 90.8, 91.1, 116.8, 120.1, 122.5, 128.3, 128.4, 128.6, 128.7, 128.9, 129.5, 131.6, 134.1, 135.2, 135.3, 140.1, 167.5. HRMS (ESI-TOF). Calcd for C₂₅H₂₂NO, [M+H]⁺ *m/z* 352.1701, Found 352.1710.



(E)-3-(4-fluorobenzylidene)-5-(4-fluorophenyl)-N-(p-tolyl)pent-4-ynamide 3b

White solid. mp: 156 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.30$ (s, 3H), 3.50 (s, 2H), 7.00-7.15 (m, 7H), 7.38-7.45 (m, 6H), 7.78 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 20.8$, 41.2, 89.7, 90.6, 115.7 (d, $J_{C-F} = 6.0$ Hz), 115.9 (d, $J_{C-F} = 6.0$ Hz), 116.5, 118.6 (d, $J_{C-F} = 4.0$ Hz), 120.1, 129.5, 130.7 (d, $J_{C-F} = 8.0$ Hz), 131.3 (d, $J_{C-F} = 3.0$ Hz), 133.5 (d, $J_{C-F} = 8.0$ Hz), 134.3, 135.1, 138.9, 162.5 (d, $J_{C-F} = 248.0$ Hz), 162.7 (d, $J_{C-F} = 249.0$ Hz), 167.4. HRMS (ESI-TOF). Calcd for

C₂₅H₂₀F₂NO, [M+H]⁺ *m/z* 388.1513, Found 388.1516.



(E)-3-(4-chlorobenzylidene)-5-(4-chlorophenyl)-N-(p-tolyl)pent-4-ynamide 3c

White solid. mp: 180 °C. ¹H NMR (400 MHz, CDCl₃): δ = 2.31 (s, 3H), 3.50 (s, 2H), 7.11 (d, J = 8.4 Hz, 2H), 7.15 (s, 1H), 7.30 (d, J = 8.8 Hz, 2H), 7.35-7.39 (m, 8H), 7.70 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 20.8, 41.2, 90.0, 91.7, 117.2, 120.1, 120.9, 128.8, 128.9, 129.5, 130.2, 132.8, 133.6, 134.3, 134.4, 134.8, 135.0, 139.0, 167.2. HRMS (ESI-TOF). Calcd for C₂₅H₂₀Cl₂NO, [M+H]⁺ *m/z* 420.0922, Found 420.0918.



(E)-3-(4-bromobenzylidene)-5-(4-bromophenyl)-N-(p-tolyl)pent-4-ynamide 3d

White solid. mp: 174 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.31$ (s, 3H), 3.49 (s, 2H), 7.12 (d, J = 9.2 Hz, 3H), 7.29-7.32 (m, 4H), 7.38 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), 7.68 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 20.9$, 41.2, 90.1, 91.9, 117.3, 120.1, 121.4, 122.7, 123.1, 129.5, 130.4, 131.8, 131.9, 133.0, 134.0, 134.4, 135.0, 139.1, 167.1. HRMS (ESI-TOF). Calcd for C₂₅H₂₀Br₂NO, [M+H]⁺ *m/z* 509.9891, Found 509.9896.



(E)-3-(4-methylbenzylidene)-N,5-di-p-tolylpent-4-ynamide 3e

White solid. mp: 169-170 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.30$ (s, 3H), 2.36 (s, 3H), 2.36 (s, 3H), 3.56 (s, 2H), 7.11 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 7.6 Hz, 2H), 7.19 (d, J = 9.2 Hz, 3H), 7.30 (d, J = 8.0 Hz, 2H), 7.38 (t, J = 8.4 Hz, 4H), 7.81 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 20.8$, 21.3, 21.5, 41.5, 90.8, 90.9, 115.9, 119.5, 120.1, 128.9, 129.2, 129.4, 129.5, 131.5, 132.5, 134.1, 135.2, 138.4, 138.8, 139.9, 167.6. HRMS (ESI-TOF). Calcd for C₂₇H₂₆NO, [M+H]⁺ *m/z* 380.2014, Found 380.2014.



(E)-3-(4-ethylbenzylidene)-5-(4-ethylphenyl)-N-(p-tolyl)pent-4-ynamide 3f

White solid. mp: 138-139 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 1.24$ (t, J = 7.6 Hz, 6H), 2.30 (s, 3H), 2.65 (q, J = 7.6 Hz, 4H), 3.56 (s, 2H), 7.10 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.19 (s, 1H), 7.22 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 7.6 Hz, 2H), 7.39 (d, J = 8.0 Hz, 4H), 7.83 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 15.3$, 15.4, 20.8, 28.6, 28.8, 41.5, 90.8, 90.9, 116.0, 119.8, 120.1, 128.0, 128.2, 128.9, 129.4, 131.6, 132.8, 134.0, 135.2, 139.9, 144.7, 145.1, 167.7. HRMS (ESI-TOF). Calcd for C₂₉H₃₀NO, [M+H]⁺ *m/z* 408.2327, Found 408.2327.



(E)-3-(4-propylbenzylidene)-5-(4-propylphenyl)-N-(p-tolyl)pent-4-ynamide 3g

White solid. mp: 126-128 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 0.94$ (t, J = 7.2 Hz, 6H), 1.59-1.68 (m, 4H), 2.30 (s, 3H), 2.58 (t, J = 7.6 Hz, 4H), 3.56 (s, 2H), 7.10 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 3H), 7.31 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 4.4 Hz, 2H), 7.40 (d, J = 4.4 Hz, 2H), 7.85 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 13.7$, 13.8, 20.8, 24.3, 24.3, 37.8, 37.9, 41.5, 90.8, 90.9, 115.9, 119.8, 120.1, 128.6, 128.8, 128.8, 129.4, 131.5, 132.8, 134.0, 135.2, 139.9, 143.1, 143.6, 167.7. HRMS (ESI-TOF). Calcd for C₃₁H₃₄NO, [M+H]⁺ *m/z* 436.2640, Found 436.2647.



(E)-3-(4-butylbenzylidene)-5-(4-butylphenyl)-N-(p-tolyl)pent-4-ynamide 3h

White solid. mp: 128-129 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 0.92$ (t, J = 7.6 Hz, 6H), 1.30-1.39 (m, 4H), 1.55-1.63 (m, 4H), 2.29 (s, 3H), 2.60 (t, J = 7.6 Hz, 4H), 3.56 (s, 2H), 7.10 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 7.6 Hz, 2H), 7.19 (d, J = 8.4 Hz, 3H), 7.31 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 6.0 Hz, 2H), 7.40 (d, J = 6.4 Hz, 2H), 7.86 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 13.9$, 20.8, 22.3, 22.3, 33.3, 33.4, 35.4, 35.6, 41.5, 90.8, 90.9, 115.9, 119.7, 120.1, 128.5, 128.7, 128.8, 129.4, 131.5, 132.7, 134.0, 135.2, 139.8, 143.3, 143.8, 167.7. HRMS (ESI-TOF). Calcd for C₃₃H₃₈NO, [M+H]⁺ *m/z* 464.2953, Found 464.2948.



(E)-3-(4-(tert-butyl)benzylidene)-5-(4-(tert-butyl)phenyl)-N-(p-tolyl)pent-4-ynamide 3i

White solid. mp: 172-174 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 1.31$ (s, 18H), 2.29 (s, 3H), 3.57 (s, 2H), 7.09 (d, J = 8.0 Hz, 2H), 7.19 (s, 1H), 7.34 (d, J = 8.4 Hz, 4H), 7.40 (d, J = 8.0 Hz, 6H), 7.91 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 20.8$, 31.1, 31.2, 34.6, 34.8, 41.5, 90.8, 90.8, 116.1, 119.6, 120.1, 125.4, 125.6, 128.7, 129.4, 131.3, 132.5, 134.0, 135.2, 139.7, 151.4, 151.9, 167.7. HRMS (ESI-TOF). Calcd for C₃₃H₃₈NO, [M+H]⁺ *m/z* 464.2953, Found 464.2963.



(E)-3-(4-pentylbenzylidene)-5-(4-pentylphenyl)-N-(p-tolyl)pent-4-ynamide 3j

White solid. mp: 129-130 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 0.89$ (t, J = 6.8 Hz, 6H), 1.31-1.32 (m, 8H), 1.57-1.64 (m, 4H), 2.30 (s, 3H), 2.60 (t, J = 7.6 Hz, 4H), 3.56 (s, 2H), 7.10 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.4 Hz, 3H), 7.31 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 5.2 Hz, 2H), 7.40 (d, J = 5.6 Hz, 2H), 7.84 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 14.0$, 20.8, 22.5, 30.9, 30.9, 31.4, 31.4, 35.7, 35.9, 41.5, 90.8, 90.9, 115.9, 119.7, 120.1, 128.6, 128.7, 128.9, 129.4, 131.5, 132.7, 134.0, 135.2, 139.9, 143.4, 143.8, 167.7. HRMS (ESI-TOF). Calcd for C₃₅H₄₂NO, [M+H]⁺ *m/z* 492.3266, Found 492.3268.



(E)-3-(3-fluorobenzylidene)-5-(3-fluorophenyl)-N-(p-tolyl)pent-4-ynamide 3k

White solid. mp: 141-142 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.30$ (s, 3H), 3.52 (s, 2H), 7.00-7.07 (m, 2H), 7.10-7.36 (m, 9H), 7.40 (d, J = 8.4 Hz, 2H), 7.68 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 20.8$, 41.1, 89.9 (d, $J_{C-F} = 4.0$ Hz), 91.4, 115.3 (d, $J_{C-F} = 21.0$ Hz), 115.7 (d, $J_{C-F} = 22.0$ Hz), 116.1 (d, $J_{C-F} = 21.0$ Hz), 117.8, 118.4 (d, $J_{C-F} = 22.0$ Hz), 120.1, 124.2 (d, $J_{C-F} = 9.0$ Hz), 124.6 (d, $J_{C-F} = 3.0$ Hz), 127.5 (d, $J_{C-F} = 3.0$ Hz), 129.5, 130.1 (d, $J_{C-F} = 8.0$ Hz), 130.3 (d, $J_{C-F} = 8.0$ Hz), 134.3, 135.0, 137.2 (d, $J_{C-F} = 8.0$ Hz), 139.2 (d, $J_{C-F} = 2.0$ Hz), 162.4 (d, $J_{C-F} = 245.0$ Hz), 167.1. HRMS (ESI-TOF). Calcd for C₂₅H₂₀F₂NO, [M+H]⁺ *m/z* 388.1513, Found 388.1517.



(E)-3-(3-chlorobenzylidene)-5-(3-chlorophenyl)-N-(p-tolyl)pent-4-ynamide 31

White solid. mp: 130 °C. ¹H NMR (400 MHz, CDCl₃): δ = 2.30 (s, 3H), 3.50 (s, 2H), 7.09 (s, 1H), 7.12 (d, *J* = 6.0 Hz, 2H), 7.22-7.34 (m, 6H), 7.38 (d, *J* = 4.4 Hz, 2H), 7.41 (d, *J* = 4.4 Hz, 2H), 7.76 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 20.8, 41.0, 89.7, 91.6, 118.1, 120.2, 124.1, 126.8, 128.4, 128.8, 128.9, 129.5, 129.6, 129.7, 129.9, 131.4, 134.3, 134.3, 134.6, 135.0, 136.9, 138.9, 167.1. HRMS (ESI-TOF). Calcd for C₂₅H₂₀Cl₂NO, [M+H]⁺ *m/z* 420.0922, Found 420.0918.



(E)-3-(3-bromobenzylidene)-5-(3-bromophenyl)-N-(p-tolyl)pent-4-ynamide 3m

White solid. mp: 112 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.29$ (s, 3H), 3.49 (s, 2H), 7.09-7.23 (m, 5H), 7.34-7.46 (m, 6H), 7.52 (m, 1H), 7.57 (m, 1H), 7.76 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 20.8$, 41.0, 89.6, 91.7, 118.1, 120.2, 122.2, 122.7, 124.4, 127.3, 129.5, 129.8, 130.1, 131.3, 131.7, 131.8, 134.3, 135.0, 137.2, 138.8, 167.1. HRMS (ESI-TOF). Calcd for C₂₅H₂₀Br₂NO, [M+H]⁺ *m/z* 509.9891, Found 509.9896.



(E)-3-(3-methylbenzylidene)-5-(m-tolyl)-N-(p-tolyl)pent-4-ynamide 3n

White solid. mp: 128-129 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.30$ (s, 3H), 2.32 (s, 3H), 2.36 (s, 3H), 3.56 (s, 2H), 7.09-7.15 (m, 4H), 7.19-7.24 (m, 4H), 7.26-7.29 (m, 3H), 7.40 (d, J = 8.4 Hz, 2H), 7.80 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 20.8$, 21.2, 21.4, 41.4, 90.8, 91.0, 116.6, 120.1, 122.4, 125.9, 128.3, 128.6, 128.7, 129.1, 129.4, 129.5, 129.6, 132.2, 134.1, 135.2, 135.3, 138.1, 138.3, 140.1, 167.6. HRMS (ESI-TOF). Calcd for C₂₇H₂₆NO, [M+H]⁺ *m/z* 380.2014, Found 380.2022.



(E)-3-(2-fluorobenzylidene)-5-(2-fluorophenyl)-N-(p-tolyl)pent-4-ynamide 30

White solid. mp: 120-122 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.30$ (s, 3H), 3.49 (s, 2H), 7.07-7.14 (m, 5H), 7.19 (t, J = 7.6 Hz, 1H), 7.27 (s, 1H), 7.29-7.35 (m, 2H), 7.42-7.48 (m, 3H), 7.63 (t, J = 7.6 Hz, 1H), 7.84 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 20.8$, 41.5, 84.5, 95.6 (d, $J_{C-F} = 3.0$ Hz), 111.1 (d, $J_{C-F} = 16.0$ Hz), 115.5 (d, $J_{C-F} = 22.0$ Hz), 118.6, 120.2, 123.0 (d, $J_{C-F} = 14.0$ Hz), 124.2 (d, $J_{C-F} = 4.0$ Hz), 124.3 (d, $J_{C-F} = 3.0$ Hz), 129.4, 130.3 (d, $J_{C-F} = 9.0$ Hz), 130.5 (d, $J_{C-F} = 3.0$ Hz), 130.5 (d, $J_{C-F} = 2.0$ Hz), 133.0 (d, $J_{C-F} = 3.0$ Hz), 133.3, 134.1, 135.2, 160.1 (d, $J_{C-F} = 247.0$ Hz), 162.7 (d, $J_{C-F} = 250.0$ Hz), 167.2. HRMS (ESI-TOF). Calcd for C₂₅H₂₀F₂NO, [M+H]⁺ *m/z* 388.1513, Found 388.1515.



(E)-3-(2-chlorobenzylidene)-5-(2-chlorophenyl)-N-(p-tolyl)pent-4-ynamide 3p

White solid. mp: 122 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.30$ (s, 3H), 3.46 (s, 2H), 7.11 (d, J = 8.0 Hz, 2H), 7.22-7.32 (m, 4H), 7.35 (s, 1H), 7.42 (d, J = 8.0 Hz, 4H), 7.53 (d, J = 6.4 Hz, 1H), 7.64 (d, J = 6.8 Hz, 1H), 7.85 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 20.8$, 41.2, 88.2, 95.4, 118.4, 120.3, 122.4, 126.7, 127.0, 129.3, 129.4, 129.6, 129.7, 129.8, 130.8, 133.3, 133.4, 133.8, 134.2, 135.1, 135.9, 137.6, 167.1. HRMS (ESI-TOF). Calcd for C₂₅H₂₀Cl₂NO, [M+H]⁺ m/z 420.0922, Found 420.0922.



(E)-3-(2,4-dimethylbenzylidene)-5-(2,4-dimethylphenyl)-N-(p-tolyl)pent-4-ynamide 3q

White solid. mp: 142-144 °C. ¹H NMR (400 MHz, CDCl₃): δ = 2.30 (s, 6H), 2.32 (s, 6H), 2.40 (s, 3H), 3.45 (s, 2H), 6.97 (d, *J* = 7.6 Hz, 1H), 7.03 (d, *J* = 6.0 Hz, 3H), 7.10 (d, *J* = 8.0 Hz, 2H), 7.20 (d, *J* = 8.4 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 1H), 7.38 (d, *J* = 8.4 Hz, 2H), 7.72 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 20.0, 20.7, 20.8, 21.2, 21.4, 41.3, 89.9, 93.9, 117.1, 119.3, 120.0, 126.5, 126.7, 128.7, 129.5, 130.4, 131.1, 131.6, 131.8, 134.0, 135.3, 136.5, 138.3, 138.6, 138.8, 140.1, 167.7. HRMS (ESI-TOF). Calcd for C₂₉H₃₀NO, [M+H]⁺ *m/z* 408.2327, Found 408.2326.



(E)-5-(thiophen-2-yl)-3-(thiophen-2-ylmethylene)-N-(p-tolyl)pent-4-ynamide 3r

White solid. mp: 139-140 °C. ¹H NMR (400 MHz, CDCl₃): δ = 2.28 (s, 3H), 3.70 (s, 2H), 6.98 (dd, J_1 = 4.0 Hz, J_2 = 4.8 Hz, 1H), 7.05-7.09 (m, 3H), 7.22 (d, J = 3.2 Hz, 2H), 7.28 (d, J = 4.4 Hz, 2H), 7.37 (d, J = 7.6 Hz, 3H), 7.69 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 20.8, 41.8, 84.6, 95.2, 113.7, 120.3, 122.7, 127.2, 127.7, 127.8, 128.0, 129.4, 130.0, 132.3, 134.1, 135.1, 138.4, 166.6. HRMS (ESI-TOF). Calcd for C₂₁H₁₈NOS₂, [M+H]⁺ *m/z* 364.0830, Found 364.0839.



(E)-5-(thiophen-3-yl)-3-(thiophen-3-ylmethylene)-N-(p-tolyl)pent-4-ynamide 3s

White solid. mp: 146-148 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.29$ (s, 3H), 3.58 (s, 2H), 7.05-7.13 (m, 4H), 7.18 (d, J = 4.4 Hz, 1H), 7.28 (dd, $J_1 = 3.2$ Hz, $J_2 = 4.8$ Hz, 1H), 7.32 (dd, $J_1 = 3.2$ Hz, $J_2 = 4.8$ Hz, 1H), 7.38 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 2.4 Hz, 1H), 7.50 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 20.8$, 41.8, 85.9, 90.9, 115.2, 120.1, 121.6, 125.6, 125.7, 126.1, 128.3, 129.0, 129.4, 129.7, 133.8, 134.1, 135.1, 136.5, 167.4. HRMS (ESI-TOF). Calcd for C₂₁H₁₈NOS₂, [M+H]⁺ *m/z* 364.0830, Found 364.0837.



(E)-3-benzylidene-N,5-diphenylpent-4-ynamide 4b

White solid. mp: 146-148 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.57 (s, 2H), 7.11 (t, *J* = 7.2 Hz, 1H), 7.24 (s, 1H), 7.29-7.35 (m, 6H), 7.38-7.41 (m, 4H), 7.48 (t, *J* = 3.2 Hz, 2H), 7.52 (d, *J* = 8.0 Hz, 2H), 7.86 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.4, 90.9, 91.0, 116.6, 120.0, 122.5, 124.5, 128.3, 128.5, 128.7, 128.9, 129.0, 131.6, 135.2, 137.7, 140.2, 167.6. HRMS (ESI-TOF). Calcd for C₂₄H₂₀NO, [M+H]⁺ *m/z* 338.1545, Found 338.1541.



(E)-3-benzylidene-N-(4-chlorophenyl)-5-phenylpent-4-ynamide 4c

White solid. mp: 170 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.56 (s, 2H), 7.24 (d, *J* = 8.8 Hz, 3H), 7.33-7.39 (m, 8H), 7.45-7.47 (m, 4H), 7.93 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.3, 90.9, 91.0, 116.4, 121.2, 122.4, 128.4, 128.5, 128.7, 128.7, 128.8, 129.0, 129.4, 131.6, 135.2, 136.3, 140.3, 167.7. HRMS (ESI-TOF). Calcd for C₂₄H₁₉ClNO, [M+H]⁺ *m/z* 372.1155, Found 372.1157.



(E)-3-benzylidene-N-(4-bromophenyl)-5-phenylpent-4-ynamide 4d

White solid. mp: 1704-175 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.57 (s, 2H), 7.24 (s, 1H), 7.32-7.36 (m, 4H), 7.39-7.42 (m, 8H), 7.46-7.48 (m, 2H), 7.84 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.4, 90.9, 91.0, 116.3, 117.1, 121.5, 122.4, 128.4, 128.5, 128.8, 128.8, 128.9, 131.6, 132.0, 135.2, 136.8, 140.4, 167.7. HRMS (ESI-TOF). Calcd for C₂₄H₁₉BrNO, [M+H]⁺ *m/z* 416.0650, Found 416.0647.



(E)-3-benzylidene-N-(4-ethylphenyl)-5-phenylpent-4-ynamide 4e

White solid. mp: 132-133 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 1.20$ (t, J = 7.6 Hz, 3H), 2.60 (q, J = 7.6 Hz, 1H), 3.56 (s, 2H), 7.13 (d, J = 8.0 Hz, 2H), 7.23 (s, 1H), 7.29-7.34 (m, 4H), 7.36-7.44 (m, 6H), 7.46-7.48 (m, 2H), 7.83 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 15.6$, 28.3, 41.3, 90.8, 91.1, 116.7, 120.2, 122.5, 128.3, 128.4, 128.6, 128.7, 128.9, 131.6, 135.3, 135.3, 140.1, 140.6, 167.5. HRMS (ESI-TOF). Calcd for C₂₆H₂₄NO, [M+H]⁺ *m/z* 366.1858, Found 366.1861.



(E)-3-benzylidene-N-(4-(tert-butyl)phenyl)-5-phenylpent-4-ynamide 4f

White solid. mp: 140 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 1.29$ (s, 9H), 3.56 (s, 2H), 7.23 (s, 1H), 7.29-7.34 (m, 6H), 7.36-7.49 (m, 8H), 7.83 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 31.3$, 34.3, 41.4, 90.8, 91.1, 116.8, 119.9, 122.5, 125.8, 128.3, 128.4, 128.6, 128.7, 128.9, 131.6, 135.1, 135.3, 140.1, 147.5, 167.5. HRMS (ESI-TOF). Calcd for C₂₈H₂₈NO, [M+H]⁺ *m/z* 394.2171, Found 394.2176.



(E)-3-benzylidene-N-(4-methoxyphenyl)-5-phenylpent-4-ynamide 4g

White solid. mp: 160-161 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.57 (s, 2H), 3.78 (s, 3H), 6.85 (d, J = 8.4 Hz, 2H), 7.24 (s, 1H), 7.34-7.49 (m, 12H), 7.71 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.3, 55.5, 90.9, 91.1, 114.2, 116.8, 122.0, 122.6, 128.4, 128.5, 128.7, 128.7, 128.9, 130.8, 131.6,

135.3, 140.2, 156.6, 167.5. HRMS (ESI-TOF). Calcd for C₂₅H₂₂NO₂, [M+H]⁺ *m/z* 368.1651, Found 368.1653.



(E)-3-benzylidene-N-(4-(methylthio)phenyl)-5-phenylpent-4-ynamide 4h

White solid. mp: 162-163 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.45$ (s, 3H), 3.56 (s, 2H), 7.21-7.25 (m, 3H), 7.32-7.48 (m, 12H), 7.80 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 16.7$, 41.4, 91.0, 91.0, 116.5, 120.6, 122.5, 128.0, 128.4, 128.5, 128.7, 128.9, 131.6, 133.9, 135.2, 135.4, 140.3, 167.6. HRMS (ESI-TOF). Calcd for C₂₅H₂₂NOS, [M+H]⁺ *m/z* 384.1422, Found 384.1425.



(E)-N-(4-acetylphenyl)-3-benzylidene-5-phenylpent-4-ynamide 4i

White solid. mp: 182-183 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.57$ (s, 3H), 3.60 (s, 2H), 7.26 (s, 1H), 7.34-7.49 (m, 10H), 7.62 (d, J = 8.0 Hz, 2H), 7.93 (d, J = 7.6 Hz, 2H), 8.02 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 26.4$, 41.5, 90.9, 91.2, 116.2, 119.0, 122.3, 128.5, 128.6, 128.8, 128.9, 129.8, 131.6, 133.1, 135.1, 140.5, 142.0, 167.9, 196.8. HRMS (ESI-TOF). Calcd for C₂₆H₂₂NO₂, [M+H]⁺ *m/z* 380.1651, Found 380.1655.



(E)-3-benzylidene-N-(4-cyanophenyl)-5-phenylpent-4-ynamide 4j

White solid. mp: 177-178 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.60 (s, 2H), 7.25 (s, 1H), 7.31-7.47 (m, 10H), 7.58 (d, *J* = 8.4 Hz, 2H), 7.65 (d, *J* = 8.0 Hz, 2H), 8.08 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.4, 90.7, 91.2, 107.3, 115.9, 118.7, 119.6, 122.2, 128.5, 128.6, 128.8, 128.8, 128.9, 131.6, 133.3, 135.1, 140.6, 141.7, 168.1. HRMS (ESI-TOF). Calcd for C₂₅H₁₉N₂O, [M+H]⁺ *m/z* 363.1497, Found 363.1504.



(E)-3-benzylidene-N-(3-chlorophenyl)-5-phenylpent-4-ynamide 4k

White solid. mp: 140 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.57 (s, 2H), 7.08 (d, *J* = 7.6 Hz, 1H), 7.19-7.24 (m, 2H), 7.32-7.39 (m, 9H), 7.47 (t, *J* = 3.6 Hz, 2H), 7.66 (s, 1H), 7.85 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.4, 90.9, 91.1, 116.4, 117.9, 120.1, 122.4, 124.5, 128.4, 128.5, 128.8, 128.8, 128.8, 130.0, 131.6, 134.7, 135.2, 138.9, 140.4, 167.7. HRMS (ESI-TOF). Calcd for C₂₄H₁₉CINO, [M+H]⁺ *m/z* 372.1155, Found 372.1145.



(E)-3-benzylidene-N-(3-bromophenyl)-5-phenylpent-4-ynamide 41

White solid. mp: 110-112 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.55 (s, 2H), 7.11 (t, *J* = 8.0 Hz, 1H), 7.21 (d, *J* = 9.6 Hz, 2H), 7.29-7.40 (m, 9H), 7.44-7.46 (m, 2H), 7.80 (s, 1H), 7.98 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.1, 90.8, 90.9, 116.5, 118.4, 122.4, 122.5, 122.9, 127.3, 128.3, 128.4, 128.6, 128.7, 130.1, 131.5, 135.2, 139.0, 140.1, 168.0. HRMS (ESI-TOF). Calcd for C₂₄H₁₉BrNO, [M+H]⁺ *m/z* 416.0650, Found 416.0646.



(E)-3-benzylidene-5-phenyl-N-(m-tolyl)pent-4-ynamide 4m

White solid. mp: 106-108 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.30$ (s, 3H), 3.55 (s, 2H), 6.91 (d, J = 7.2 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 7.23 (s, 1H), 7.28-7.33 (m, 5H), 7.36-7.40 (m, 5H), 7.47 (d, J = 3.2 Hz, 2H), 7.83 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 21.4$, 41.4, 90.9, 91.1, 116.7, 117.1, 120.7, 122.5, 125.3, 128.3, 128.4, 128.6, 128.7, 128.8, 128.9, 131.6, 135.3, 137.7, 138.9, 140.1, 167.6. HRMS (ESI-TOF). Calcd for C₂₅H₂₂NO, [M+H]⁺ *m/z* 352.1701, Found 352.1710.



(E)-3-benzylidene-N-(2-fluorophenyl)-5-phenylpent-4-ynamide 4n

White solid. mp: 132-133 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.60 (s, 2H), 7.04-7.09 (m, 2H), 7.12-7.16 (m, 1H), 7.31-7.35 (m, 4H), 7.39-7.44 (m, 4H), 7.49-7.51 (m, 2H), 8.14 (s, 1H), 8.38 (t, J = 8.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.6, 90.7, 91.0, 114.8 (d, J_{C-F} = 19.0 Hz), 116.4, 121.8, 122.5, 124.4 (d, J_{C-F} = 8.0 Hz), 124.6 (d, J_{C-F} = 4.0 Hz), 126.4 (d, J_{C-F} = 10.0 Hz), 128.4, 128.5 (d, J_{C-F} = 31.0 Hz), 128.7, 128.9, 131.7, 135.3, 140.3, 152.5 (d, J_{C-F} = 242.0 Hz), 167.7. HRMS (ESI-TOF). Calcd for C₂₄H₁₉FNO, [M+H]⁺ *m/z* 356.1451, Found 356.1461.



(E)-3-benzylidene-N-(2-chlorophenyl)-5-phenylpent-4-ynamide 40

White solid. mp: 140-141 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.63 (s, 2H), 7.01-7.05 (m, 1H), 7.25-7.34 (m, 7H), 7.38-7.42 (m, 4H), 7.48-7.50 (m, 2H), 8.41 (s, 1H), 8.45 (d, *J* = 8.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.8, 91.0, 91.0, 116.4, 121.7, 122.7, 123.0, 124.8, 127.7, 128.4, 128.6, 128.7, 128.9, 129.0, 131.7, 134.7, 135.3, 140.4, 167.8. HRMS (ESI-TOF). Calcd for C₂₄H₁₉CINO, [M+H]⁺ *m/z* 372.1155, Found 372.1157.



(E)-3-benzylidene-N-(2-bromophenyl)-5-phenylpent-4-ynamide 4p

White solid. mp: 140-141 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.63 (s, 2H), 6.95-6.99 (m, 1H), 7.29-7.34 (m, 6H), 7.38-7.42 (m, 4H), 7.48-7.51 (m, 3H), 8.36 (s, 1H), 8.43 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.9, 91.0, 91.1, 113.6, 116.4, 122.0, 122.7, 125.3, 128.3, 128.4, 128.6, 128.7, 128.9, 131.7, 132.3, 135.3, 135.8, 140.5, 167.8. HRMS (ESI-TOF). Calcd for C₂₄H₁₉BrNO, [M+H]⁺ *m/z* 416.0650, Found 416.0644.



(E)-3-benzylidene-5-phenyl-N-(o-tolyl)pent-4-ynamide 4q

White solid. mp: 170-171 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.21$ (s, 3H), 3.63 (s, 2H), 7.06 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 7.2 Hz, 1H), 7.20-7.25 (m, 2H), 7.34-7.35 (m, 4H), 7.38-7.48 (m, 6H), 7.77 (s, 1H), 7.93 (d, J = 8.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 17.6$, 41.5, 90.8, 91.3, 116.7, 122.5, 122.8, 125.2, 126.8, 128.4, 128.5, 128.7, 128.9, 128.9, 130.4, 131.6, 135.2, 135.7, 140.3, 167.6. HRMS (ESI-TOF). Calcd for C₂₅H₂₂NO, [M+H]⁺ *m/z* 352.1701, Found 352.1698.



(E)-3-benzylidene-N-(2,4-dichlorophenyl)-5-phenylpent-4-ynamide 4r

White solid. mp: 130-131 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 3.62$ (s, 2H), 7.25-7.41 (m, 11H), 7.48 (d, J = 3.6 Hz, 2H), 8.37 (s, 1H), 8.43 (d, J = 9.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 41.8, 90.9, 91.1, 116.2, 122.4, 122.6, 123.5, 127.8, 128.4, 128.4, 128.7, 128.8, 128.9, 129.2, 131.7, 132.5, 133.5, 135.2, 140.5, 167.8. HRMS (ESI-TOF). Calcd for C₂₄H₁₈Cl₂NO, [M+H]⁺ <math>m/z$ 406.0765, Found 406.0771.



(E)-3-benzylidene-N-(naphthalen-1-yl)-5-phenylpent-4-ynamide 4s

White solid. mp: 160 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.73 (s, 2H), 7.19 (t, *J* = 7.6 Hz, 1H), 7.33-7.49 (m, 11H), 7.50 (d, *J* = 3.6 Hz, 2H), 7.68 (d, *J* = 8.0 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 1H), 7.91 (d, *J* = 8.4 Hz, 1H), 8.06 (d, *J* = 7.2 Hz, 1H), 8.36 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.6, 91.2, 91.5, 116.6, 120.6, 122.5, 125.7, 125.9, 126.3, 127.0, 128.5, 128.5, 128.7, 128.8, 128.8, 129.0, 131.8, 132.2, 134.1, 135.2, 140.6, 168.1. HRMS (ESI-TOF). Calcd for C₂₈H₂₂NO, [M+H]⁺ *m/z* 388.1701, Found 388.1693.



(E)-3-benzylidene-5-phenyl-N-(quinolin-8-yl)pent-4-ynamide 4t

White solid. mp: 88-90 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.72 (s, 2H), 7.29-7.37 (m, 6H), 7.41 (t, *J* = 7.6 Hz, 2H), 7.49-7.56 (m, 6H), 8.10-8.12 (m, 1H), 8.46-8.47 (m, 1H), 8.86 (d, *J* = 7.2 Hz,

1H), 10.48 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 42.1, 90.7, 91.3, 116.6, 117.0, 121.4, 121.6, 123.0, 127.2, 127.8, 128.0, 128.2, 128.3, 128.5, 128.9, 131.7, 134.6, 135.5, 136.0, 138.5, 139.7, 148.1, 168.2. HRMS (ESI-TOF). Calcd for C₂₇H₂₁N₂O, [M+H]⁺ *m/z* 389.1654, Found 389.1646.



(E)-3-(4-ethylbenzylidene)-5-(4-ethylphenyl)-N-(quinolin-8-yl)pent-4-ynamide 4u

White solid. mp: 170-171 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 1.21-1.26$ (m, 6H), 2.61-2.68 (m, 4H), 3.72 (s, 2H), 7.12 (d, J = 8.0 Hz, 2H), 7.22-7.25 (m, 3H), 7.34-7.37 (m, 1H), 7.41-7.45 (m, 4H), 7.48-7.56 (m, 2H), 8.10-8.12 (m, 1H), 8.47 (dd, $J_1 = 1.2$ Hz, $J_2 = 4.4$ Hz, 1H), 8.85 (d, J = 7.6 Hz, 1H), 10.49 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 15.4$, 15.4, 28.7, 28.8, 42.2, 90.7, 90.9, 116.4, 116.7, 120.4, 121.5, 121.6, 127.3, 127.8, 127.9, 128.1, 129.0, 131.8, 133.2, 134.7, 136.1, 138.7, 139.5, 144.3, 144.7, 148.2, 168.5. HRMS (ESI-TOF). Calcd for C₃₁H₂₉N₂O, [M+H]⁺ *m/z* 445.2280, Found 445.2283.



(*E*)-3-(4-formylbenzylidene)-5-(4-formylphenyl)-*N*-(quinolin-8-yl)pent-4-ynamide 4v
White solid. mp: 173-174 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.73 (s, 2H), 7.06 (s, 1H), 7.42 (dd, J₁ = 4.0 Hz, J₂ = 8.0 Hz, 1H), 7.52-7.61 (m, 4H), 7.82 (d, J = 7.2 Hz, 2H), 7.93 (d, J = 7.6 Hz, 2H), 8.06 (d, J = 8.0 Hz, 2H), 8.17 (d, J = 8.0 Hz, 1H), 8.58 (d, J = 4.0 Hz, 1H), 8.81 (d, J = 7.2 Hz, 2H)

1H), 10.01 (s, 1H), 10.03 (s, 1H), 10.36 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 48.4, 91.9, 96.8, 116.9, 117.9, 121.6, 121.9, 127.5, 128.0, 128.6, 129.2, 129.5, 129.7, 132.3, 134.2, 135.8, 135.9, 136.6, 138.2, 138.3, 141.7, 148.0, 167.4, 191.2, 191.6. HRMS (ESI-TOF). Calcd for C₂₉H₂₁N₂O₃, [M+H]⁺ *m/z* 445.1552, Found 445.1561.



(*E*)-dimethyl 4,4'-(2-(2-oxo-2-(quinolin-8-ylamino)ethyl)but-1-en-3-yne-1,4-diyl)dibenzoate 4w

White solid. mp: 165-166 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 3.69$ (s, 2H), 3.92 (s, 3H), 3.93 (s, 3H), 7.01 (s, 1H), 7.39 (dd, $J_1 = 4.0$ Hz, $J_2 = 8.0$ Hz, 1H), 7.49-7.56 (m, 4H), 7.97 (d, J = 8.4 Hz, 4H), 8.07 (d, J = 8.0 Hz, 2H), 8.13 (d, J = 8.4 Hz, 1H), 8.54 (d, J = 4.0 Hz, 1H), 8.81 (d, J = 7.2 Hz, 1H), 10.37 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 48.4$, 52.1, 52.2, 91.1, 96.7, 116.7, 117.1, 121.6, 121.8, 127.2, 127.4, 127.9, 128.6, 129.5, 129.5, 129.7, 130.0, 131.6, 134.3, 136.4, 138.1, 138.4, 140.3, 148.0, 166.3, 166.7, 167.6. HRMS (ESI-TOF). Calcd for C₃₁H₂₅N₂O₅, [M+H]⁺ *m/z* 505.1763, Found 505.1764.



(E)-3-(3-acetoxybenzylidene)-5-(3-acetoxyphenyl)-N-(quinolin-8-yl)pent-4-ynamide 4x

Colorless oil. ¹H NMR (400 MHz, CDCl₃): $\delta = 2.26$ (s, 3H), 2.29 (s, 3H), 3.70 (s, 2H), 7.04 (d, J = 5.2 Hz, 2H), 7.22-7.55 (m, 10H), 8.11 (d, J = 8.4 Hz, 1H), 8.52 (d, J = 4.4 Hz, 1H), 8.83 (d, J = 7.2 Hz, 1H), 10.40 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 21.0$, 21.1, 41.9, 90.0, 91.7, 116.7, 117.9, 121.4, 121.5, 121.7, 122.0, 122.0, 124.3, 124.8, 126.4, 127.3, 127.9, 129.2, 129.2, 129.5, 134.5, 136.2, 136.9, 138.4, 138.9, 148.2, 150.4, 150.7, 167.8, 169.0, 169.3. HRMS (ESI-TOF). Calcd for C₃₁H₂₅N₂O₅, [M+H]⁺ *m/z* 505.1763, Found 505.1752.



(*E*)-3-(3-((*tert*-butyldimethylsilyl)oxy)benzylidene)-5-(3-((*tert*-butyldimethylsilyl)oxy)phenyl)-*N*-(quinolin-8-yl)pent-4-ynamide 4y

Colorless oil. ¹H NMR (400 MHz, CDCl₃): $\delta = 0.15$ (s, 6H), 0.18 (s, 6H), 0.95 (s, 18H), 3.73 (s, 2H), 6.79 (d, J = 8.0 Hz, 2H), 6.97 (s, 2H), 7.08-7.15 (m, 3H), 7.24-7.28 (m, 2H), 7.35 (dd, $J_1 = 4.0$ Hz, $J_2 = 8.0$ Hz, 1H), 7.47-7.55 (m, 2H), 8.10 (d, J = 8.0 Hz, 1H), 8.54 (d, J = 4.0 Hz, 1H), 8.85 (d, J = 7.6 Hz, 1H), 10.43 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = -4.5$, -4.5, 18.1, 18.1, 25.6, 42.0, 90.5, 91.0, 116.7, 117.2, 120.0, 120.5, 120.6, 121.5, 121.6, 122.1, 123.2, 124.1, 125.1, 127.3, 127.9, 129.2, 129.6, 134.6, 136.1, 136.9, 138.5, 139.7, 148.2, 155.4, 155.7, 168.1. HRMS (ESI-TOF). Calcd for C₃₉H₄₉N₂O₃Si₂, [M+H]⁺ *m/z* 649.3282, Found 649.3276.



(*E*)-3-(3-acetamidobenzylidene)-5-(3-acetamidophenyl)-*N*-(quinolin-8-yl)pent-4-ynamide 4z White solid. mp: 142-143 °C. ¹H NMR (400 MHz, CDCl₃): δ = 2.09 (s, 6H), 3.63 (s, 2H), 7.02 (s, 1H), 7.11-7.14 (m, 3H), 7.23-7.30 (m, 2H), 7.41-7.49 (m, 4H), 7.58 (d, *J* = 6.4 Hz, 1H), 7.65 (d, *J* = 7.6 Hz, 1H), 8.02 (d, *J* = 8.4 Hz, 1H), 8.25 (s, 1H), 8.42 (s, 1H), 8.46 (s, 1H), 8.72 (s, 1H), 10.34 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 24.4, 24.4, 41.8, 90.5, 91.2, 116.7, 117.2, 119.9, 120.0, 120.2, 121.6, 122.0, 122.8, 123.4, 124.6, 127.1, 127.4, 127.8, 128.8, 129.2, 134.2, 136.0, 136.2, 138.2, 138.3, 138.4, 139.4, 148.3, 168.5, 169.0, 169.1. HRMS (ESI-TOF). Calcd for C₃₁H₂₇N₄O₃, [M+H]⁺ *m/z* 503.2083, Found 503.2094.



(E)-5-(pyridin-3-yl)-3-(pyridin-3-ylmethylene)-N-(quinolin-8-yl)pent-4-ynamide 4aa

White solid. mp: 172-173 °C. ¹H NMR (400 MHz, CDCl₃): δ = 3.70 (s, 2H), 7.22-7.27 (m, 2H), 7.39-7.42 (m, 2H), 7.51-7.57 (m, 2H), 7.76 (d, *J* = 7.2 Hz, 1H), 8.08 (d, *J* = 8.0 Hz, 1H), 8.14 (d, *J* = 8.4 Hz, 1H), 8.55-8.84 (m, 6H), 10.36 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 41.8, 88.0, 93.8, 116.7, 119.1, 119.9, 121.7, 121.9, 122.9, 123.6, 127.3, 127.9, 131.3, 134.3, 135.9, 136.3, 136.6, 138.4, 138.6, 148.2, 148.8, 149.0, 150.0, 152.4, 167.3. HRMS (ESI-TOF). Calcd for C₂₅H₁₉N₄O, [M+H]⁺ *m/z* 391.1559, Found 391.1546.



IV. Structure Analysis X-Ray Crystallography of 3b

Compound	3b
Empirical formula	$C_{25}H_{19}F_2NO$
Formula weight	387.41
Crystal system	Monoclinic
Space group	P 21/c
<i>a</i> (Å)	12.515(3)
<i>b</i> (Å)	8.4989(17)
<i>c</i> (Å)	19.132(4)
α (°)	90
β (°)	95.95(3)
γ (°)	90
V (Å3)	2024.1(7)
Z	4
D/g cm-3	1.271
μ/mm-1	0.090
F(000)	808.0
Parameters	263
R _{int}	0.0844
GOF	1.075
wR_2^b (all data)	0.3009

V. Mechanistic Study

1. Radical Inhibition Experiments



Additive	Yield ^[b] (%)
none	80
TEMPO (2 equiv)	70
BHT (2 equiv)	68

[a] Standard conditions: **1a** (0.96 mmol), **2a** (0.4 mmol), CuI (10 mol %), Phen (10 mol %) and K₂CO₃ (2.0 equiv) in dioxane (0.8 mL) under air atmosphere at 120 °C for 1 h. [b] Yield of the isolated product.

2. Control Experiment

To probe the reaction mechanism, compounds **5-8** were prepared as possible reaction intermediate that may be constructed from any two coupling partners, and reacted with another coupling partner under the standard reaction conditions. We conducted the following experiments.



Following the general procedure II.2, to a solution of **5** (80.8 mg, 0.4 mmol) in 1,4-dioxane (0.8 mL) was added 2-chloro-*N*-(*p*-tolyl)acetamide **2a** (73.2 mg, 0.4 mmol), Phen (7.9 mg, 0.04 mmol), CuI (7.6 mg, 0.04 mmol), and K₂CO₃ (110.6 mg, 0.8 mmol) under air in screw-cap test tube. The reaction mixture was stirred at 120 °C for 1.0 h. After the reaction finished, **3a** was not detected in the reaction. This result suggested that **5** might not be the active intermediate.



Following the general procedure II.2, to a solution of **6** (81.6 mg, 0.4 mmol) in 1,4-dioxane (0.8 mL) was added 2-chloro-*N*-(*p*-tolyl)acetamide **2a** (73.2 mg, 0.4 mmol), Phen (7.9 mg, 0.04 mmol), CuI (7.6 mg, 0.04 mmol), and K_2CO_3 (110.6 mg, 0.8 mmol) under air in screw-cap test tube. The reaction mixture was stirred at 120 °C for 1.0 h. After the reaction finished, **3a** was not detected in the reaction. This result suggested that **6** might not be the active intermediate.



Following the general procedure II.2, to a solution of 7 (94.2 mg, 0.3 mmol) in 1,4-dioxane (0.6 mL) was added the 1-ethyl-4-ethynylbenzene **1f** (51 μ L, 0.36 mmol), Phen (5.4 mg, 0.03 mmol), CuI (5.7 mg, 0.03 mmol), and K₂CO₃ (82.8 mg, 0.6 mmol) under air in screw-cap test tube. The reaction mixture was stirred at 120 °C for 1.0 h. After the reaction finished, the reaction mixture was cooled to room temperature and quenched by water. The mixture was extracted with EtOAc (3.0 mL×3), the combined organic phases were dried over anhydrous Na₂SO₄ and the solvent was evaporated under vacuum. The residue was purified by column chromatography to give the corresponding products **4u** (40.0 mg, 30%). This result also suggested that **7** might be the active intermediate.



Following the general procedure II.2, to a solution of **8** (94.2 mg, 0.3 mmol) in 1,4-dioxane (0.6 mL) was added the 1-ethyl-4-ethynylbenzene **1f** (51 μ L, 0.36 mmol), Phen (5.4 mg, 0.03 mmol), CuI (5.7 mg, 0.03 mmol), and K₂CO₃ (82.8 mg, 0.6 mmol) under air in screw-cap test tube. The reaction mixture was stirred at 120 °C for 1.0 h. After the reaction finished, the reaction mixture was cooled to room temperature and quenched by water. The mixture was extracted with EtOAc (3.0 mL×3), the combined organic phases were dried over anhydrous Na₂SO₄ and the solvent was evaporated under vacuum. The residue was purified by column chromatography to give the corresponding products **4u** (42.5 mg, 32%). This result also suggested that **8** might be the active intermediate.

Conclusions:

When 5 and 6 were used as starting material under the standard reaction conditions, 3a was not detected in the reaction. By the treatment 1-ethyl-4-ethynylbenzene 1f with 7 or 8 under the standard reaction conditions, the desired product 4u was observed. These results suggested that 7 and 8 is a highly probable reaction intermediate that can be generated in situ from 1-ethyl-4-ethynylbenzene 1f and 2-chloro-*N*-(quinolin-8-yl)acetamide 2t via Sonogashira reactions. Furthermore, ESI/MS experiments were performed to gain evidence for the possible intermediates 7 and 8 in the proposed mechanism. A mixture of 1f (0.96 mmol), 2t (0.4 mmol), CuI (10 mol %), Phen (10 mol %) and K₂CO₃ (2.0 equiv) in dioxane (0.8 mL) was reacted at 90 °C for 10 minutes and 50 μ L of the mixture was used for the ESI analysis in CH₃OH. The ESI/MS analyses showed a peak at m/z 315.1505, which was identified as intermediates 7 and 8.



VI. References

- [1] J.-H. Li, Y. Liang, Y.-X. Xie, J. Org. Chem. 2005, 70, 4393.
- [2] Y. Liu, J. Yang, W. Bao, Eur. J. Org. Chem. 2009, 5317.
- [3] J. Li, D. Ding, L. Liu, J. Sun, RSC Adv. 2013, 3, 21260.
- [4] Y. Lv, W. Pu, X. Zhu, T. Zhao, F. Lin, Adv. Synth. Catal. 2018, 360, 1397.

VII. ¹H and ¹³C NMR Spectra of Compounds 3 and 4

Product 3a





S31



S32



S33











S36

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10






- 252 - 255 -













S44



S45





















210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10





210 200 190 180 170 180 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10